Search results
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 2 hours agoPhase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and of ...
Why is a mother’s mental health so important? A doctor explains
Plus via Yahoo News· 2 days agoWen: Here is the good news. A variety of effective treatments are available to treat postpartum ...
An AI blood test purports to diagnose postpartum depression
Washington Post· 4 days agoPostpartum depression is a leading cause of maternal death, but its diagnosis and treatment is spotty at best, negligent at worst. Now ...
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN...
The Herald Journal· 2 days agoLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that dosing of subjects has been completed in the pivotal pharmacokinetic (PK) study designed to support a New < ...
Reunion raises over $100M to build a better psychedelic drug
BioPharma Dive via Yahoo Finance· 1 day agoThe funding will help Reunion pay for a mid-stage study testing its most advanced medicine —...
Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo...
Benzinga· 1 day agoReunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, today announced the close of a $103 million Series A financing co-led ...
Whites Not the Predominant Victims of 'Deaths of Despair'
Medscape· 1 day agoDeaths of despair — defined as midlife deaths from suicide, drug overdose, and alcoholic liver...
Mental Health Awareness Month kicks off with an urgent report on Black maternal mental health
TheGrio via Yahoo News· 1 day agoA new report found that maternal mental health is a leading cause of maternal mortality, especially...
MPM BioImpact-owned Reunion raises $103M, one of the largest rounds for a psychedelic biotech
FierceBiotech· 1 day agoIt’s taken decades for psychedelics to regain clinical and regulatory relevance. Reunion Neuroscience has cashed in on a $103 million series A, building on the promise of a phase 2-stage psychedelic ...
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
Zacks via Yahoo Finance· 7 days agoSage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales...